News
Trailblazing technology can detect acute pressure changes in heart

Researchers have used cutting-edge imaging technology to measure acute pressure changes inside the heart – work that has also helped them pinpoint why a widely used drug given to help calculate blood flow through the organ causes breathlessness in some patients.
The state-of-the-art technology uses magnetic resonance imaging (MRI) to create detailed pictures of the heart.
Using the new technology, the team from the University of East Anglia in the UK discovered that pressure inside the heart goes up when a specific medication called adenosine is given for testing blood flow.
They also found out why adenosine – which is a naturally occurring substance that relaxes and dilates the blood vessels and is used to help restore normal heartbeats in people with certain rhythm disorders – makes patients breathless during the test.
The team – whose work has been published in the journal BMC Cardiovascular Disorders – say their findings could help doctors better diagnose and monitor patients with heart disease and heart failure.
Lead researcher Dr Pankaj Garg, from UEA’s Norwich Medical School, said: “When patients present with symptoms of heart disease, doctors use a special test called heart MRI to take detailed pictures of the heart and see how well it is working.
“Sometimes, patients are given a special medication called adenosine during the heart MRI test to see how blood flows through the heart, and it can cause breathlessness.
“We wanted to better understand the way that the heart functions, and why patients become breathless when given adenosine.”
The UEA team worked with researchers at the University of Leeds and studied 33 patients referred for a stress cardiac MRI.
This test is performed to help evaluate the blood flow in the heart arteries, looking for blockages.
The research team took pictures of the patient’s heart when it was resting and when it was working hard after being given adenosine.
Dr Garg explained: “Adenosine mimics the effect of exercise on the heart while the patient is lying down on the scanner. And we discovered why it makes patients get out of breath.
Postgraduate researcher Hosamadin Assadi, also from UEA’s Norwich Medical School, added: “We looked at the top chamber of the heart, called the left atrium, and also looked at the lower part of the heart, called the left ventricle.
“We used advanced software to measure and study the heart, and we also estimated the pressures inside the heart before and after giving the medication.
“Our study shows that after giving patients adenosine, the heart’s left atrium got bigger really fast – just before the blood flowed out.
“This is important as it shows that the previously published heart MRI pressure model is adaptable to acute changes in the heart and can be more broadly used to diagnose and monitor heart disease – in particular heart failure.
“We also found that a measure called LVFP, which tells us about the pressure inside the heart, went up when the heart was working hard.”
Dr Garg’s previous work showed that a 4D heart MRI scan can create detailed flow images of the heart, and how this non-invasive imaging technique can measure the peak velocity of blood flow in the heart accurately and precisely.
The scan takes just six to eight minutes and can provide precise imaging of the heart valves and the flow inside the heart in three-dimensions, helping doctors determine the best course of treatment for patients.
“This work strengthens the notion of using heart MRI to measure pressures inside the heart,” Dr Garg said.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.













